--- title: "Danaher Corporation (DHR.US)" type: "quote" locale: "en" url: "https://longbridge.com/en/quote/DHR.US.md" symbol: "DHR.US" name: "Danaher Corporation" industry: "生命科學工具與服務" --- # Danaher Corporation (DHR.US) | Item | Detail | |------|--------| | Industry | 生命科學工具與服務 | | Location | 美股市場 | | Website | [www.danaher.com](https://www.danaher.com) | ## Company Profile 丹納赫公司在美國、中國及國際市場設計、制造和銷售專業、醫療、研究和工業產品及服務。其業務分為生物技術、生命科學和診斷三個部門。生物技術部門提供生物加工技術、耗材、服務和解決方案,以推動、加速和整合治療藥物的開發和生產;細胞系和細胞培養基開發服務;用于生產的細胞培養基、工藝液體和緩衝液;色譜樹脂、過濾技術和無菌灌裝;一次性硬件、耗材和服務,如全套生產設施的設計和安裝;實驗室過濾、分離和純化;實驗室規模的蛋白質純化和分析工具;用于診斷和檢測開發的試劑、膜和服務;以及醫療過濾解決方案。生命科學部門提供質譜儀;生物分析測量系統;流式細胞術、基因組學、實驗室自動化、離心、液體處理自動化儀器、抗體以及顆粒... ## Financial Score > *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.* > Updated: 2026-02-15T04:30:13.000Z **Overall: C (0.46)** **Industry**: Life Sciences Tools and Services | Metric | Value | |--------|-------| | Industry Ranking | 13 / 60 | | Industry Median | C | | Industry Average | C | - **Style**: Value - Stocks where the company's main business is in a mature stage. - **Scale**: Large - The company has stable operations, allowing for dependable long-term returns. ### Score Analysis **Style Score**: #### Growth Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | 2.90% | | | Net Profit YoY | -7.31% | | #### Value Score: | Indicator | Value | Rating | |-----------|-------|--------| | P/B Ratio | 2.86 | | | Dividend Ratio | 0.60% | | **Size Score**: #### Market Cap Score: | Indicator | Value | Rating | |-----------|-------|--------| | Market Cap | 150.27B | | #### Revenue Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue | 24.57B | | **Multi Score**: C #### Profit Score: B | Indicator | Value | Rating | |-----------|-------|--------| | ROE | 7.05% | C | | Profit Margin | 14.71% | B | | Gross Margin | 59.11% | B | #### Growth Score: C | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | 2.90% | C | | Net Profit YoY | -7.31% | C | | Total Assets YoY | 7.64% | B | | Net Assets YoY | 6.04% | B | #### Cash Score: C | Indicator | Value | Rating | |-----------|-------|--------| | Cash Flow Margin | 679.80% | C | | OCF YoY | 2.90% | C | #### Operating Score: D | Indicator | Value | Rating | |-----------|-------|--------| | Turnover | 0.31 | D | #### Debt Score: B | Indicator | Value | Rating | |-----------|-------|--------| | Gearing Ratio | 37.05% | B | ```chart-data:radar { "title": "Longbridge Financial Score - Danaher Corporation", "chart_type": "radar", "dimensions": [ { "name": "Profit", "grade": "B", "indicators": [ { "name": "ROE", "value": "7.05%", "rating": "C" }, { "name": "Profit Margin", "value": "14.71%", "rating": "B" }, { "name": "Gross Margin", "value": "59.11%", "rating": "B" } ] }, { "name": "Growth", "grade": "C", "indicators": [ { "name": "Revenue YoY", "value": "2.90%", "rating": "C" }, { "name": "Net Profit YoY", "value": "-7.31%", "rating": "C" }, { "name": "Total Assets YoY", "value": "7.64%", "rating": "B" }, { "name": "Net Assets YoY", "value": "6.04%", "rating": "B" } ] }, { "name": "Cash", "grade": "C", "indicators": [ { "name": "Cash Flow Margin", "value": "679.80%", "rating": "C" }, { "name": "OCF YoY", "value": "2.90%", "rating": "C" } ] }, { "name": "Operating", "grade": "D", "indicators": [ { "name": "Turnover", "value": "0.31", "rating": "D" } ] }, { "name": "Security", "grade": "B", "indicators": [ { "name": "Gearing Ratio", "value": "37.05%", "rating": "B" } ] } ] } ``` ### Peer Comparison | Rank | Name | Profit | Growth | Operation | Security | Cash | Rating | |------|------|--------|--------|-----------|----------|------|--------| | 01 | ChromaDex (US.CDXC) | A | A | A | B | B | A | | 02 | 安捷倫科技 (US.A) | A | C | B | C | C | B | | 03 | 沃特世 (US.WAT) | A | B | B | C | C | B | | 04 | 藥明生物(ADR) (US.WXXWY) | B | B | D | A | B | B | | 05 | 西氏醫藥服務 (US.WST) | B | B | B | B | C | B | ## Valuation Analysis | Metric | Current | Industry Ranking | High | Median | Low | |--------|---------|-----------------|------|--------|-----| | PE (TTM) | 41.58 | 17/59 | 44.89 | 41.43 | 37.47 | | PB | 2.86 | 32/59 | 3.08 | 2.88 | 2.72 | | PS (TTM) | 6.12 | 42/59 | 6.47 | 6.15 | 5.84 | | Dividend Yield | 0.60% | 4/59 | 0.60% | 0.57% | 0.54% | ## Institutional View ### Analyst Rating Distribution > As of 2026-02-13T05:00:00.000Z Total Analysts: **26** | Rating | Count | Percentage | |--------|-------|-----------| | Buy | 18 | 69% | | Overweight | 4 | 15% | | Hold | 3 | 12% | | Underweight | 0 | 0% | | Sell | 0 | 0% | ### Target Price Forecast | Metric | Price | |--------|-------| | Current Price | 212.58 | | Highest Target | 310.00 | | Lowest Target | 220.00 | ## References - [Company Overview](https://longbridge.com/en/quote/DHR.US/overview.md) - Shareholders, executives, business segments - [Financials](https://longbridge.com/en/quote/DHR.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan - [Topics & Discussions](https://longbridge.com/en/quote/DHR.US/topics.md) - Community topics and discussions --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.